Each tablet contains 15 mg of meloxicam (Meloxicamum)
Short-term symptomatic treatment of exacerbations of osteoarthritis. Long-term symptomatic treatment of rheumatoid arthritis or ankylosing spondylitis.
This medicinal product is contraindicated in the following situations: hypersensitivity to the active substance or to any of the excipients or to substances with a similar action, e.g. non-steroidal anti-inflammatory drugs (NSAIDs), aspirin; meloxicam should not be given to patients who have developed signs of asthma, nasal polyps, angio-oedema or urticaria following the administration of aspirin or other NSAIDs; third trimester of pregnancy and when breastfeeding; in children and adolescents below 15 years of age; history of gastrointestinal bleeding or perforation, related to previous NSAIDs therapy; active, or history of recurrent gastric and/or duodenal ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding); severely impaired liver function; non-dialysed severe renal failure; gastrointestinal bleeding, history of cerebrovascular bleeding or other bleeding disorders; severe heart failure.
This is a drug. For safety, use it according to the package insert and only when necessary. If in doubt, consult your doctor or pharmacist.
phone: (+48 22) 742 00 22
informacjaoleku@hasco-lek.pl
Each tablet contains 15 mg of meloxicam (Meloxicamum)
Short-term symptomatic treatment of exacerbations of osteoarthritis. Long-term symptomatic treatment of rheumatoid arthritis or ankylosing spondylitis.
This medicinal product is contraindicated in the following situations: hypersensitivity to the active substance or to any of the excipients or to substances with a similar action, e.g. non-steroidal anti-inflammatory drugs (NSAIDs), aspirin; meloxicam should not be given to patients who have developed signs of asthma, nasal polyps, angio-oedema or urticaria following the administration of aspirin or other NSAIDs; third trimester of pregnancy and when breastfeeding; in children and adolescents below 15 years of age; history of gastrointestinal bleeding or perforation, related to previous NSAIDs therapy; active, or history of recurrent gastric and/or duodenal ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding); severely impaired liver function; non-dialysed severe renal failure; gastrointestinal bleeding, history of cerebrovascular bleeding or other bleeding disorders; severe heart failure.
Przedsiębiorstwo Produkcji
Farmaceutycznej
Hasco-Lek S.A.
st. Żmigrodzka 242e
51-131 Wroclaw
phone: (+48) 71 352 95 22
fax: (+48) 71 352 76 36
hasco@hasco-lek.pl
